Changes in hepatic fibrosis and incidence of HCC following direct-acting antiviral treatment of F3 chronic hepatitis c patients: a prospective observational study

Abstract

Aim: Studies of clinical outcomes in chronic hepatitis C (CHC) patients with pretreatment advanced liver fibrosis (F3) after sustained virologic response (SVR) are scarce, and most studies are of small cohorts and retrospective in nature. Our aim was to assess the clinical outcomes following direct acting antiviral (DAA) treatment among hepatitis C F3 patients after SVR.

Methods: This study included 1517 chronic hepatitis C patients with F3 fibrosis receiving DAAs in the out-patient clinics at the Egyptian Liver Research Institute and Hospital (ELRIAH). We included patients 18 years or older with HCV who received DAAs, have F3 by transient elastography, and have no history of hepatocellular carcinoma (HCC). Patients were followed up every six months after end of treatment using ultrasonography and AFP.

Results: Significant improvement of fibrosis occurred with decreases in LSM, FIB-4, APRI, and FIB-6. When changes in LSM were categorized depending on delta LSM, 873 patients (57.5%) showed regression, 454 (29.9%) were stable, and 190 patients (12.5%) showed progression of fibrosis. Overall, 33 cases developed HCC during follow-up with incidence rate of 0.915/100 py (95%CI: 0.64-1.27). Incidence was high with progression of liver fibrosis (6.17/100 py) compared to patients with stable fibrosis (1.09/100 py) and regression of liver fibrosis (0.75/100 py). There were no significant differences as regards fibrosis indicators at baseline (LSM, FIB-4, APRI, and FIB-6) between those who developed HCC and those who did not.

Conclusion: CHC Patients with F3 fibrosis showed a high rate of regression of fibrosis and decreased HCC incidence after achieving SVR following DAAs.

Keywords

HCC / fibrosis changes / F3 / DAAs

References

[1] Bruix J.American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update.Hepatology2011;53:1020-2 PMCID:PMC3084991

[2] Feld JJ,Hézode C.ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection.N Engl J Med2015;373:2599-607

[3] Loo N,Mann J.Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance.Medicine (Baltimore)2019;98:e16254 PMCID:PMC6617322

[4] van der Meer AJ,Hofer H.Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.J Hepatol2017;66:485-93

[5] Association for Study of Liver., Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis.J Hepatol2015;63:237-64

[6] Tsochatzis EA,Ntaoula S,Davidson BR.Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy.J Hepatol2011;54:650-9

[7] Tapper EB.Use of liver imaging and biopsy in clinical practice.N Engl J Med2017;377:2295-7

[8] Association for the Study of the Liver. Electronic address: [e-mail]., European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018.J Hepatol2018;69:461-511

[9] Association for the Study of the Liver. Electronic address: [e-mail]., Clinical Practice Guidelines Panel: Chair:., EASL Governing Board representative:., Panel members:. EASL recommendations on treatment of hepatitis C: Final update of the series^*.J Hepatol2020;73:1170-218

[10] Romano A,Piovesan S.Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study.J Hepatol2018;69:345-52

[11] Piñero F,Ridruejo E.LALREAN. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.Liver Int2019;39:1033-43

[12] Shiha G,Soliman R,Adel Elbasiony M.Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: a prospective study.J Viral Hepat2020;27:671-9

[13] Sánchez-Azofra M,García-Buey ML.Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals.Liver Int2021;41:2885-91

[14] AASLD/IDSA HCV Guidance Panel.Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.Hepatology2015;62:932-54

[15] World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. 2014.

[16] CIOMS/WHO. International ethical guidelines for biomedical research involving human subjects. Geneva: CIOMS. 1993.

[17] Association for the Study of the Liver. Electronic address: [e-mail]., European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[18] Bonder A.Utilization of FibroScan in clinical practice.Curr Gastroenterol Rep2014;16:372

[19] Fraquelli M,Casazza G.Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease.Gut2007;56:968-73 PMCID:PMC1994385

[20] Shiha GE,Bahgat M.Chronic hepatitis c patients with obesity: do we need two operators for accurate evaluation of liver stiffness?.Ann Hepatol2018;17:795-801

[21] Lin ZH,Dong QJ.Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis.Hepatology2011;53:726-36

[22] Sterling RK,Clumeck N.APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.Hepatology2006;43:1317-25

[23] Shiha G,Mikhail NNH.Development and multicenter validation of FIB-6: a novel, machine learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in patients with chronic hepatitis C.Hepatol Res2022;52:165-75

[24] Heimbach JK,Finn RS.AASLD guidelines for the treatment of hepatocellular carcinoma.Hepatology2018;67:358-80

[25] Omata M,Kokudo N.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.Hepatol Int2017;11:317-70 PMCID:PMC5491694

[26] Marrero JA,Sirlin CB.Diagnosis, Staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases.Hepatology2018;68:723-50

[27] Shiha G,Mikhail N,Serwah A.Changes in hepatic fibrosis stages after achieving SVR following direct-acting anti-viral treatment: a prospective study.GastroHep2020;2:39-48

[28] Mantovani A.Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease.Ann Transl Med2017;5:270 PMCID:PMC5515814

[29] Adami HO,Nyrén O.Excess risk of primary liver cancer in patients with diabetes mellitus.J Natl Cancer Inst1996;88:1472-7

[30] El-Serag HB,Everhart JE.The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans.Am J Gastroenterol2001;96:2462-7

[31] Davila JA,Shaib Y,El-Serag HB.Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study.Gut2005;54:533-9 PMCID:PMC1774454

[32] El-Serag HB,Javadi F.The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.Clin Gastroenterol Hepatol2006;4:369-80

[33] Wang C,Gong G.Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies.Int J Cancer2012;130:1639-48

[34] Yang WS,Bray F.The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies.PLoS One2011;6:e27326 PMCID:PMC3244388